Adjuvant Capecitabine Effective in Biliary Tract Cancer

​ With a five-year overall survival rate under 10%, the outlook is poor for individuals diagnosed with biliary tract cancer. Only 20% of patients are eligible for surgical resection with the intent to cure the disease. In addition, until this point, no studies have identified a beneficial adjuvant therapy. In order to remedy this problem, the researchers of the BILCAP study (EudraCT 2005-003318-13), a phase 3 clinical trial featuring a collaboration of 44 specialist hepato-pancreato-biliary cent...
Continue reading

Adding Docetaxel to Androgen Suppression and Radiotherapy in High-Risk Prostate Cancer: An Interview With Seth A. Rosenthal, MD, FACR, FASTRO

Of the 20% of patients with prostate cancer who have high-risk disease, around 30% to 40% experience a relapse following initial treatment. Less than 50% of these patients are cured. A phase 3 clinical trial, the NRG Oncology trial NRG-RTOG 0521, reports a way to improve survival for patients with nonmetastatic, high-risk prostate cancer: adding docetaxel to a standard regimen consisting of radiotherapy (RT) and long-term androgen suppression (AS) . In this interview with i3 Health, Seth A. Rose...
Continue reading

High-Risk Prostate Cancer: Adding Docetaxel Increases Survival

A phase 3 clinical trial reports that adding docetaxel to a standard regimen consisting of radiotherapy and long-term androgen suppression (AS) therapy improves outcomes for men with high-risk nonmetastatic prostate cancer. In the United States, prostate cancer is the second leading cause of cancer-related death among men. Of the 20% of patients whose prostate cancer is considered high risk, around 30% to 40% experience a relapse following initial treatment. Less than 50% of these patients are c...
Continue reading

Preventing Venous Thromboembolism in Patients With Cancer: An Interview With Philip Wells, MD, FRCPC, MSc

​ Venous thromboembolism is the third most common vascular condition after heart attack and stroke, affecting between 300,000 and 600,000 individuals in the United States each year. Patients with active cancer are at increased risk, with a 9.6% chance of developing symptomatic thrombosis during the first six months of chemotherapy. In this interview with i3 Health, hematologist Philip Wells, MD, FRCPC, MSc, Chair and Chief of the Department of Medicine at the University of Ottawa and The Ottawa ...
Continue reading

Apixaban Prevents Venous Thromboembolism in Patients With Cancer

​ A team of Canadian researchers has found that apixaban reduces the occurrence of venous thromboembolism in cancer patients who are starting chemotherapy and are at intermediate to high risk for this condition. A blood clot that forms in the veins, venous thromboembolism is the third most common vascular condition after heart attack and stroke, affecting between 300,000 and 600,000 individuals in the United States each year. Patients with active cancer are at increased risk, with a 9.6% chance ...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.